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We investigated whether patients with well documented IgE mediated allergy to chlorhexidine (anaphylaxis) do also react with Alexidine in vitro.
Background: Chlorhexidine (CHX) is a widely utilised disinfectant for skin and mucosal surfaces as well as medical devices. CHX is a biguanide compound with two chlorophenyl endings linked by a hexamethylene chain. CHX can cause rare IgE-mediated anaphylaxis. Alexidine (ALX), also a biguanide with similar hexamethylene center but without aromatic endings, has similar bactericidal properties and represents a potential substitute for CHX. The allergic potential of ALX is unknown.
Methods:
We investigated whether patients with IgE to CHX also react with ALX. We performed inhibition assays with CHX, chlorguanide (CG) and ALX using a commercial IgE assay for CHX (ImmunoCAP, ThermoFisher Scientific, Uppsala). In addition, we performed basophil activation tests (BAT, CD63 and CD203a as activation markers) with CHX and ALX.
Results: 24 patients from Switzerland with allergic reactions to CHX and 9 sera with elevated CHX-specific IgE from Australian patients were included. In 22 patients with CHX-specific IgE >0.7 kU/L CAP inhibition studies were performed. CG showed a strong inhibitory effect (>60%) in 19/22 and CHX in 8/22 tested sera, while ALX (>60%) inhibited CHX positivity in 2/22 sera when it was used at 67 times higher concentration than CHX. 10/21 patients showed a positive BAT with CHX. ALX was stimulatory only if basophils were pretreated with IL-3 (3/22), but not in normal BAT (0/22). One patient was positive for ALX but not for CHX.
Conclusion:
The IgE response to CHX appears to be polyclonal: CG seems to be the main epitope, and is best accessible as free CG, followed by the bivalent CHX. ALX with its biguanide epitopes appears to react with some of the CHX specific IgE, but both inhibition-tests and BAT assays show that this cross-reactivity is weak and of questionable functional relevance.
P21 SKIN TESTING AND ORAL CHALLENGE FOR PENICILLIN ALLERGY: A SINGLE CENTRE EXPERIENCE
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Introduction: Approximately 10% of patients in the clinical setting claim to be allergic to penicillin, however most have no demonstrable allergy. This study was to demonstrate the safety of a rapid de-labelling protocol, and assess the incidence of positive skin testing or oral challenge.
Methods: A retrospective analysis was conducted with patients in the allergy and immunology clinic evaluated for penicillin allergy. All patients with negative specific IgE test to penicillins, underwent skin prick testing, followed by intradermal skin testing (SPT/IDT) for penicillin and its determinant (commercial Kit penicillin allergenic determinants (PPL and DAP-MDM; Diater Laboratories). An oral challenge with phenoxymethylpenicillin or amoxicillin was performed in those with both negative skin testing. Clinical details of the patients and the reactions were noted.
Results: One hundred and fifty patients underwent testing over a period of 1 year, of these 100 where female and fifty were men. One hundred and twelve patients had testing for self-described reactions to penicillin, five for unknown drug and thirty-three for self-reported reaction to another class of antibiotic. Of these patients, 27 had a history of anaphylaxis to penicillin or cephalosporin. There was one true positive skin prick test of which he had a history of anaphylaxis to cephalosporin. Five patients had positive intradermal tests. Of the 136 oral challenges undertaken only seven were positive. Three had a mild immediate reaction and three were delayed mild reactions.
Conclusion:
A minority of patients presenting with a history of penicillin allergy had an immune-mediated hypersensitivity (9/150, 6%) in this study. For patients with no history of anaphylaxis skin prick test was negative in all cases. Predictors for positive skin test were symptoms less than 12 h and anaphylaxis to cephalosporin. There were no clinical predictors for a reaction to oral challenge, however all reactions were non-severe. Results: There were 96 presentations to ED with anaphylaxis. 69 (65%) were grade 2 and 21 (26%) were grade 3 reactions. No grade was assigned for 6 (6%) identified by ACI staff as anaphylaxis. Food was the most common trigger, accounting for 57 (59%) of presentations. No cause was identified in 13 (13.5%) of cases.
P22 ANAPHYLAXIS RISK MANAGEMENT PROGRAM ENHANCES EMERGENCY CARE OF ANAPHYLAXIS
A total of 90 adrenaline doses were administered to 72 (75%) presentations; the route was intramuscular for 86 (96%) of doses. 73 (76%) were observed in hospital for 4 or more hours.
Adrenaline auto-injectors were prescribed to 60 (63%) of all presentations with anaphylaxis. 47 (48%) were discharged with an anaphylaxis action plan. Case note alerts were completed for 24 (25%) presentations. 47 (48%) were referred to specialist ACI services or were already receiving specialist management. Sydney University, Sydney, Australia
Conclusion
Self-reported penicillin allergy is common among patients attending ED. It is a poor predictor of true penicillin allergy. This study hypothesised that using a combination of skin testing and oral challenge the majority of patients with self-reported penicillin allergy could be de-labelled.
Methods: Patients 18-85 years of age presenting to ED with self-reported penicillin allergy were eligible for study. Skin prick (SPT) and intradermal (ID testing) with positive and negative controls, major and minor penicillin determinants (Diater kits, AMSL) and amoxicillin were performed in ED. After negative testing a graded amoxicillin challenge given over 9 days was performed. The primary end point was the allergy status of the patient at the end of the study.
Results: 100 patients completed the study. Mean age: 42 AE 14 years, 54% were females. Of these 81% (95% CI 71.9-88.2) were negative to both skin testing and challenge. There were 16 positive skin tests (2 SPT and 14 ID) 
